Aspen Neuroscience and Bambusa Therapeutics announce plans to go public amid biotech IPO surge
Aspen Neuroscience, a cell therapy company backed by Gilead, and Bambusa Therapeutics, an I&I biotech founded by former BioNTech scientists, have each filed paperwork to launch initial public offerings.
The moves come as the biotech sector experiences renewed IPO activity, with companies seeking capital to advance development programs. Aspen focuses on Parkinson's disease cell therapies, while Bambusa is developing immuno-oncology candidates.
By going public, both firms aim to raise funds to support clinical trials and expand their pipelines, positioning themselves for growth in a competitive market.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Parkinson's cell therapy biotech Aspen and I&I startup Bambusa file for IPOs”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that